Similarly, several studies investigate the modulation of FHL proteins as novel therapeutic strategies, either through the use of miRNA or shRNA that target FHL2 (mostly as a cancer therapy (Brun et al. 2013; Huang et al. 2019)), or through FHL1 overexpression (to treat muscular dystrophy (D'Arcy et al. 2014)). Here, FHL2 is linked to cancer.